Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence

“Scanxiety” and a sense of control: the perspective of lung cancer survivors and their caregivers on follow-up - a qualitative study

(2023) Katharina Seibel et al.   BMC Psychology

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS)

(2021) P.G. Casali et al.   ANNALS OF ONCOLOGY

Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2021) P.G. Casali et al.   ANNALS OF ONCOLOGY

Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre and Post-imatinib Eras

(2019) Michael J. Cavnar et al.   ANNALS OF SURGERY

Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour

(2017) Lorenzo D'Ambrosio et al.   EUROPEAN JOURNAL OF CANCER

The cross-national epidemiology of specific phobia in the World Mental Health Surveys

(2017) K. J. Wardenaar et al.   PSYCHOLOGICAL MEDICINE

Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies

(2016) Kjetil Søreide et al.   Cancer Epidemiology

Gastrointestinal stromal tumors (GISTs) and second malignancies

(2016) Maria Grazia Rodriquenz et al.   MEDICINE

Unknown

(2016)   JOURNAL OF SURGICAL ONCOLOGY

Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature

(2015) Jaclyn Frances Hechtman et al.   ANNALS OF SURGICAL ONCOLOGY

Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery

(2015) H. Joensuu et al.   EUROPEAN JOURNAL OF CANCER

KITandPDGFRAMutations and the Risk of GI Stromal Tumor Recurrence

(2015) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Answers to Common Questions About the Use and Safety of CT Scans

(2015) Cynthia H. McCollough et al.   MAYO CLINIC PROCEEDINGS

Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib – Analysis of prognostic factors (EORTC-STBSG collaborative study)

(2014) S. Bauer et al.   EJSO

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rational Follow-Up After Curative Cancer Resection

(2013) Matthew J. Furman et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastrointestinal Stromal Tumor of the Rectum: Results of Surgical and Multimodality Therapy in the Era of Imatinib

(2012) Jens Jakob et al.   ANNALS OF SURGICAL ONCOLOGY

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

(2012) Heikki Joensuu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Natural History of Imatinib-naive GISTs

(2011) Sabrina Rossi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

(2011) Heikki Joensuu et al.   LANCET ONCOLOGY

Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors

(2010) C. A. Thompson et al.   ANNALS OF ONCOLOGY

Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?

(2009) C. Mussi et al.   ANNALS OF ONCOLOGY

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

(2009) Jason S Gold et al.   LANCET ONCOLOGY

Risk stratification of patients diagnosed with gastrointestinal stromal tumor

(2008) Heikki Joensuu   HUMAN PATHOLOGY